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Summary The study was planned to compare, in a prospective double-blind randomized trial, the efficacy and safety of toremifene (TOR)
and tamoxifen (TAM) in post-menopausal patients with advanced breast cancer who have not had prior systemic therapy for advanced
disease. Four hundred and fifteen post-menopausal patients with oestrogen receptor (ER)-positive or ER-unknown advanced breast cancer
were randomly assigned to receive daily either 60 mg TOR or 40 mg TAM. The patients were stratified to measurable and non-measurable
but evaluable groups. They were assessed for response to therapy, time to progression (TTP), time to treatment failure (TTF), response
duration, overall survival and drug toxicity. Two hundred and fourteen patients were randomized into TOR and 201 into TAM treatment. The
response rate (complete + partial) was 31.3% for TOR and 37.3% for TAM (P= 0.215). The 95% confidence interval (Cl) for the 6% difference
was -15.1% to 3.1%. The median TTP was 7.3 months for TOR and 10.2 months for TAM (P = 0.047). The 95% Cl for the hazard ratio of 0.80
was 0.64-1.00. A percentage of the TOR patients (9.8%) and the TAM patients (18.9%) discontinued the treatment prematurely (P = 0.011)
for various reasons. Consequently, the median TTF of 6.3 vs 8.5 months did not differ significantly (P= 0.271). The hazard ratio was 0.89 and
the subsequent 95% Cl 0.73-1.09. The median overall survival was 33.0 months for TOR and 38.7 months for TAM (P= 0.645). The hazard
ratio was 0.94 with 95% Cl of 0.73-1.22. The transient difference in TTP may be related to an imbalance in ER content of the tumours. When
only patients with ER-positive tumours were considered (n = 238), no difference between two treatments was seen (P = 0.578). TAM was
associated with an overall slightly higherfrequency of adverse drug reactions than TOR (44.3 vs 39.3%) and a higher discontinuation rate due
to these events (3.5% vs 0.9%). Treatment-emerged moderate dizziness (P = 0.026) and cataracts (P = 0.026) were more frequent among
TAM than among TOR patients. In conclusion, TOR (60 mg day1) and TAM (40 mg day-1) are equally effective and safe in the treatment of
advanced post-menopausal ER-positive or ER-unknown breast cancer.
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Tamoxifen (TAM) is the most common alternative for initial
endocrine therapy of patients with recurrent or metastatic breast
cancer. The overall response rate of post-menopausal women to
TAM varies from 20% to 60% (Jaiyesimi et al, 1995). This wide
range is largely due to the variability of prognostic factors in
different study populations and to heterogeneous quality assess-
ment. TAM, when given as an adjuvant treatment, is associated
with a 20% mortality reduction (Santen et al, 1990; Early Breast
Cancer Trialists' Collaborative Group, 1992).
The presence of oestrogen receptors (ERs) in the breast cancer
cells is the most important factor associated with successful treat-
ment with TAM. Approximately 70% of al primary breast cancers
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in post-menopausal women contain ER and tumour growth is
dependent on oestrogens. TOR and TAM have both oestrogenic
and antioestrogenic effects which are dependent on species,
gender, time of treatment, organ and end point of measurement
(Kangas, 1992a).
Generally TAM is well tolerated. The most common adverse
drug reaction consists in climacteric-like symptoms, but the drug
has also been reported to generate DNA adducts in human hepato-
cyte cultures and in rats and Syrian hamsters (Han et al, 1992;
White et al, 1992; Hard et al, 1993). TAM is a liver carcinogen in
rats (Hirsimaki et al, 1993; Vancutsem et al, 1994) and it increases
the risk of endometrial and gastrointestinal cancers in patients
(Fisher et al, 1994; De Gregorio et al, 1995; Rutqvist et al, 1995)
and increases the number of polyps in the endometrium (Lahti et
al, 1993). Clearly, an anti-oestrogen that lacks these carcinogenic
characteristics while retaining the beneficial effects of TAM is
desirable (Zito, 1994).
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Toremifene (TOR) is a new antioestrogen and a pharmacolog-
ical analogue of TAM (Kangas, 1992b; Kivinen and Maenpaa,
1990) having both oestrogenic and antioestrogenic properties
(Kallio et al, 1986). In breast cancer, TOR blocks the oestrogen-
mediated growth stimulus of tumour cells (Kangas et al, 1986) by
a mechanism that includes the regulation of oncogene expression
and growth factors and induction of apoptosis (Vuorio et al, 1988;
Warri et al, 1993).
The toxicology of TOR resembles that of TAM, except for the
carcinogenicity, which is less than that of tamoxifen according to
animal studies. Nor does TOR generate DNA adducts in the rat
liver (White et al, 1992; Hard et al, 1993). In a 2-year study in rats
TOR was not carcinogenic (Karlsson et al, 1996).
More than 1000 post-menopausal breast cancer patients have
been included in ongoing and completed phase II studies with
TOR. The dose has ranged from 20 mg to 400 mg day-' (Valavaara
et al, 1988; Valavaara and Pyrhonen, 1989; Hietanen et al, 1990;
Pyrhonen et al, 1990; Hamm et al, 1991). TOR has been used as
first-, second- or third-line treatment after previous hormonal or
cytotoxic treatment has failed (Valavaara et al, 1988; Valavaara
and Pyrhonen, 1989; Hietanen et al, 1990; Pyrhonen et al, 1990;
Hamm et al, 1991; Jonsson et al, 1991; Tominaga et al, 1993; Vogel
et al, 1993; Pyrhonen et al, 1994). At a dose of 40-240 mg day-',
TOR has been well tolerated as first-line treatment in advanced
ER-positive or undetermined breast cancer. The response rates
have ranged between 43% and 61% (Valavaara et al, 1988;
Hietanen et al, 1990; Tominaga et al, 1993). Consequently, a few
large phase III studies were initiated comparing tamoxifen with
toremifene (Pyrhonen, 1990; Hayes et al, 1995).
The aim ofthe present study was to compare the safety and effi-
cacy of TOR 60 mg day-' with TAM 40 mg day-' in the treatment
ofpost-menopausal patients with advanced breast cancer.
PATIENTS AND METHODS
Study design
This study is a double-blind, parallel group, randomized multi-
centre clinical study. A total of 415 women were enrolled in 26
centres in six countries. The study was initiated in Finland in 1986.
Later, it was extended to Sweden, Norway, Poland, Hungary and
the Czech Republic.
Patient eligibility
Eligible patients were post-menopausal (I year since the last
menstruation or age 55 years if a hysterectomy had been
performed) and had histologically or cytologically verified inoper-
able primary, metastatic or recurrent breast cancer with at least one
measurable or evaluable (bone disease) lesion. ER status had to be
positive or unknown. Prior adjuvant therapy was allowed ifat least
12 months had elapsed since the last endocrine treatment or the
patient had fully recovered from cytotoxic therapy. The anticipated
survival had to be at least 3 months and the Karnofsky perfor-
mance status . 50%. Patients were excluded if they had severe
concomitant renal, hepatic, cardiac, diabetic or thromboembolic
diseases or other malignancies; basal cell cancer of the skin or
cervical carcinoma in situ were allowed. Continuous use of
corticosteroids for diseases other than cancer was allowed only ifit
had been started 6 months before randomization. Patients who
were not considered able to cooperate were also excluded. Written
or documented verbal informed consent was required. The study
was approved by the ethics committees in each participating
hospital.
Randomization and treatment
The patients were stratified by whether or not they had measurable
or only evaluable disease and were randomly assigned to treatment
with TOR or TAM. Randomization was performed centrally, using
computer generated lists that were prepared separately for both
stratification groups and for each participating centre.
The study medications were provided by Orion-Farmos as
tablets containing either 60 mg of TOR or 40 mg of TAM. The
dose of TAM was chosen on the basis of clinical practice in
Scandinavia and the dose ofTOR was based on the previous phase
II results (Valavaara et al, 1988). The dosage for both arms was
one tablet by mouth daily, preferably at breakfast time. The treat-
ment continued until disease progression or adverse events
precluded the use of the drug. Minimum treatment period was 2
months. The patients were required to return all unused tablets,
which were counted and recorded to assess treatment compliance.
Patient evaluation and response criteria
All patients had a complete history and physical examination no
earlier than 4 weeks before the treatment: blood chemistry, haemo-
globin, a leucocyte and platelet count, a chest radiograph, a
skeletal scintigraphy, an abdominal sonography or computerized
tomography (CT) scan and assessment of performance status. If
the scintigraphy revealed bone metastasis, a radiograph was then
obtained to verify the finding. All lesions, signs and symptoms
were registered.
The follow-up examinations were performed bimonthly for 2
years and thereafter at 4-month intervals. At each follow-up a
careful clinical examination was done and the same blood tests
were taken as at baseline. In case of multiple bone metastasis, at
least four and invariably more than 30% of the lesions were evalu-
ated bimonthly except for the skeletal scintigraphy which was
taken every fourth month. In case of a negative baseline result, a
chest radiograph, an abdominal sonography or CT scan and
skeletal scintigraphy were performed twice annually. All adverse
events were registered and the degree ofcausality to the study drug
was evaluated.
The study met the GCP standards with 100% source data verifi-
cation during the study. The responses were evaluated according to
the WHO criteria adopted by the UICC (Miller et al, 1981).
Treatment response (CR, PR, NC) was accepted only ifconfirmed
at two consecutive evaluations 2 months apart. All objective
responses and the duration of the response were re-evaluated and
approved by the investigator's review board. Time to progression
(TTP) was defined as the time between randomization and onset of
relapse or disease progression. Patients who had discontinued the
study prematurely and patients who were still continuing in the
study were treated as censored observations from the time of
randomization until the time ofdiscontinuation, or until the time of
the latest follow-up visit (before 31 December 1993) respectively.
Time to treatment failure (TTF) was defined as the period from the
day of randomization to the day when disease progression, treat-
ment-related toxicity, resulting in discontinuation of therapy or
death (from any cause) occurred.
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Table 1 Patient characteristics
Treatment arm
Toremifene Tamoxifen
(n = 214) (n = 201)
Characteristic
Mean age (range)a
Mean disease free interval (range)a
Mean number of organ sites (range)b
Stratificational groupb
Measurable
Non-measurable
Dominant site of diseaseb
Visceral
Bone
Soft tissue
Karnofsky Performance statusd
100
80-90
60-70
40-50
Prior hormonal therapye
No
Yes
ER status
Known
Unknown
PR status
Known
Unknown
65.5 (33.6-87.6)
4.7 (0.0-32.9)
2.2 (1.0-7.0)
163 (76.2)c
49 (22.9)
60 (28.0)
68 (31.8)
84 (39.3)
58 (27.1)
117 (54.7)
32 (15.0)
6 (2.8)
201 (93.9)
13 (6.1)
121 (56.5)
93 (43.5)
109 (50.9)
105 (49.1)
65.9(44.8-90.2)
4.0 (0.0-33.8)
2.3 (1.0-8.0)
152 (75.6)
45 (22.4)
63 (31.3)
70 (34.8)
64 (31.8)
50 (24.9)
111 (55.2)
33 (16.4)
6 (3.0)
Table 2 Response rates to toremifene and tamoxifen
Treatment arm
Toremifene Tamoxifen
All randomizedpatients (n = 214) (n = 201)
Complete response 19 (8.9)a 19 ( 9.5)
Partial response 48 (22.4) 56 (27.9)
Stable disease 50 (23.4) 52 (25.9)
Progressive disease 83 (38.8) 55 (27.4)
Not evaluable 14 ( 6.5) 19 ( 9.5)
Complete and partial response 67 (31.3) 75 (37.3)
Eligible and evaluable patients (n= 186) (n = 173)
Complete response 18 ( 9.7) 18 (10.4)
Partial response 46 (24.7) 53 (30.6)
Stable disease 47 (25.3) 51 (29.5)
Progressive disease 75 (40.3) 51 (29.5)
Complete and partial response 64 (34.4) 71 (41.0)
aNumber (%) of patients.
183 (91.0)
17 (8.5)
117 (58.2)
84 (41.8)
112 (55.7)
89 (44.3)
Cox's regression model was fitted for each of these variables to
obtain an estimate for the hazard ratio (TAM/TOR) and the corre-
sponding 95% confidence interval (CI).
RESULTS
aln years, data not available for zero and one patient respectively; bdata not
available for two and four patients respectively; cnumber (%) of patients;
ddata not available for one and one patients respectively; eData not available
for zero and one patient respectively.
Statistics
A total of344 evaluable patients were required in order to detect a
15% difference in response rates between TOR and TAM with a
two-sided type I error rate (a) of0.05 and a type II error rate (e) of
0.20. The assessment of treatment efficacy was based on the two
primary variables, that is response rate and time to progression. A
conservative testing procedure was obtained by demanding a
statistically significant testing result at the 0.05 level for both of
these variables or at the 0.025 level for one of them, in case the
other one remained statistically insignificant.
All data were independently verified for correctness of entry
and subjected to both manual and computerized checks for logic
and consistency before being made available for statistical
analysis. Efficacy and safety were assessed by the intent to treat
principle when at least 70% of the enrolled patients had experi-
enced progressive disease. The corresponding data cut-off date
was 31 December 1993.
The comparisons between TOR and TAM arms with respect to
qualitative variables were made using either Fisher's exact test or
Pearson's chi-square test. In case of quantitative variables
Wilcoxon's rank-sum test was applied. The log-rank test was used
to compare the two treatment arms with regard to duration vari-
ables (i.e. TTP, TTF, response duration and overall survival) and
Patient characteristics
Between June 1986 and May 1992, 415 patients (TOR 214, TAM
201) were accrued. Nineteen patients in the TOR arm (ER-negative
tumour, four patients; non-measurable disease other than bone,
three patients each; premenopausal patients, two patients; inade-
quate baseline examinations two; other eight) and 17 in the TAM
arm (non-measurable disease other than bone, five patients; ER-
negative tumour, three patients; the concurrent presence of a
second active malignancy, three patients; other six) were ineligible.
The median follow-up period ofthe patients was 25.2 months. The
characteristics ofthe patient populations before treatment are listed
in Table 1. These characteristics are evenly balanced between the
two arms except forthe levels ofER receptors: in the TAM group a
larger proportion ofpatients had high ER levels, which is reflected
by mean ER concentrations (119 and 171 fmol mg-' cytosolprotein
for TOR and TAM patients respectively).
Response
Response data are presented in Table 2. The response rates were
calculated for all randomized patients as well as for all eligible
and all evaluable patients separately. There were 19 complete
responses in both treatment arms and 48 vs 56 partial responses
with TOR and TAM arm respectively. The rates of complete plus
partial responses for TOR and TAM were 31.3% and 37.3%
respectively. The difference was not statistically significant
(P = 0.215). The 95% CI for the difference was -15.1% to 3.1%.
The median time to the onset of objective response for all
randomized patients was 3.9 months with TOR and 2.6 months
with TAM (P = 0.455). The median duration of complete and
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Table 3 Time to progression, time to treatment failure and overall survival of
patients on toremifene and tomoxifen (all randomized patients)
Treatment arm
Toremifene Tamoxifen
(n = 214) (n = 201)
Median (mean) time to progressiona,b 7.3 (13.0) 10.2 (15.3)
Number (%) of patients with PD 176 (82.2) 147 (73.1)
Median (mean) time to treatment failurea 6.3 (12.2) 8.5 (12.7)
Number (%) of patients failed 195 (91.1) 181 (90.0)
Median (mean) overall survivala 33.0 (37.5) 38.7 (37.5)
Number (%) of patients dead 123 (57.5) 115 (57.2)
amn months from randomization; bp = 0.047
1.0
0.8
1.0
0.8
.0
0-
0.6
0.4
0.2
0.0
0 5 10 15 20 25 30 35 40 45
Time to progression (months)
Figure 2 Time to progression among toremifene (-, n = 121) and
tamoxifen (. . ., n = 117) treated oestrogen receptor-positive patients.
(P= 0.578, log-rank test)
0.6
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0.0
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0.8
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Figure 1 Time to progression among toremifene (-, n= 214) and
tamoxifen (. . ., n = 201) treated patients (P = 0.047, log-rank test)
partial responses were 26.3 and 18.3 months for TOR and 26.4 and
18.4 months for TAM respectively. There was no significant
difference in either response group (CR: P = 0.224; PR: P =
0.706). Lesions in different sites responded similarly to both treat-
ments (data not shown).
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80
Survival time (months)
Figure 3 Overall survival among toremifene (-, n = 214) and tamoxifen
(. . ., n = 201) treated patients (P = 0.645, log-rank test). Survival time was
defined as the time between randomization and death. Patients who were
alive were treated as censored observations from the time of randomization
until the last date they were known to be alive (before 31 December 1993)
Time to progression and time to treatment failure
At the time ofdata cut-off, 19 (8.9%) patients were continuing on
the study without evidence ofdisease progression on TOR and 20
(10%) on TAM. The results ofTTP and TTF arepresented in Table
3 and Figures 1 and 2. There was a transient difference between
the TTP curves, which approached statistical significance,
favouring TAM over TOR (P = 0.047). The median TTP was 7.3
months (95% CI 5.8-8.8) for TOR patients and 10.2 months (95%
CI 8.1-12.5) for TAM. The hazard ratio for disease progression
was 0.801 (95% CI 0.640-1.00). The mean TTPs were 13.0 and
15.3 months for TOR and TAM respectively. Owing to the higher
incidence oftreatment discontinuations in the TAM arm, there was
no difference in TTF between TOR and TAM (median 6.3 and 8.5
and mean 12.2 and 12.7 respectively; P = 0.271). Hazard ratio for
1TF was 0.89 (95% CI 0.73-1.09).
Further analysis confirmed that the slight difference of TTP
may be due to an imbalance in the prognostic factors, as the
outcome of the two treatments was similar in patients with ER-
positive tumours (Figure 2) and the difference was mainly due to
the effects encountered in patients with tumours of unknown ER
status. For these patients the median TTP on TOR was 6.3 months
(95% Cl 4.4-8.0) and on TAM 11.4 months (95% Cl 8.1-14.4)
(P = 0.019), whereas for the patients with ER-positive tumours
the TTP was 9.1 (95% CI 4.6-11.6) and 10.1 months (95% Cl
6.5-12.5) (P = 0.578). With regard to TTF, the ER status yielded
analogous P-values of0.103 and 0.984 respectively.
Survival
Of the 415 randomized patients, 238 had died by the data cut-off
date; 123 patients in the TOR arm and 115 in the TAM arm.
Survival data are presented in Table 3 and Figure 3. The median
survival time forpatients treated with TOR was 33.0 months (95%
CI 28.5-37.0) and 38.7 months (95% CI 31.8-41.9) for those
treated with TAM (P = 0.645).
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Table 4 Adverse events associated with toremifene and tamoxifen
(treatment related or indeterminate cause)
Treatment arm
Toremifene Tamoxifen
Event (n = 214) (n = 201)
Sweating
All 31 (14.5)a 23 (11.4)
Moderate/severeb 8 (3.7) 3 (1.5)
Hot flaushes
All 24 (11.2) 21 (10.4)
Moderate/severe 5 (2.3) 8 (4.0)
Nausea
All 12 (5.6) 19 (9.5)
Moderate/severe 3 (1.4) 6 (3.0)
Vaginal discharge
All 12 (5.6) 7 (3.5)
Moderate/severe 3 (1.4) 0 (0.0)
Oedema
All 4 (1.9) 6 (3.0)
Moderate/severe 2 (0.9) 1 (0.5)
Dizziness
Allc 3 (1.4) 10 (5-0)
Moderate/severed 0 (0.0) 5 (2.5)
Vomiting
All 3 (1.4) 3 (1.5)
Moderate/severe 3 (1.4) 2 (0.9)
Vaginal bleeding
All 2 (0.9) 3 (1.5)
Moderate/severe 0 (0.0) 1 (0.5)
aNumber (%) of patients; bby WHO severity grading; cp = 0.048; dp= 0.026.
Table 5 Premature study discontinuations
Treatment arm
Toremifene Tamoxifen
Reason (n = 214) (n = 201)
Death 4 (1.9)a 10 (5.0)
Lost to follow-up 1 (0.5) 6 (3.0)
Othertherapy 5 (2.3) 7 (3.5)
Intercurrent illness 5 (2.3) 4 (2.0)
Adverse event/refusal 2 (0.9) 7 (3.5)
Protocol violation 2 (0.9) 0 (0.0)
Other 2 (0.9) 4 (2.0)
Totalb 21 (9.8) 38 (18.9)
aNumber (%) of patients; bp 0.011.
Toxicity
Overall, TAM therapy was associated with a slightly higher
frequency of adverse events than TOR (44.3% vs 39.3%). The
major adverse events are presented in Table 4. Most ofthe adverse
events were mild or moderate. Only four patients (three sweating,
one hot flushes, nausea, vomiting and oedema) on TOR and six
patients (four nausea, one sweating, one vaginal bleeding) on
TAM experienced severe adverse events. Moderate dizziness was
reported significantly more often (P = 0.026) among TAM patients
than among TOR patients.
Table 6 Other treatment emergent adverse events
Treatment arm
Toremifene Tamoxifen
Event (n = 214) (n = 201)
Thromboembolic events 11 (5.1)a 11 (5.5)
Cardiac events 7 (3.3) 7 (3.5)
Ocular abnormalitiesb 3 (1.4) 7 (3.5)
Neoplasms 5 (2.3) 8 (4.0)
Elevated liver function testsc
Alkaline phosphatase 13 (6.0) 16 (8.0)
SGOTd 6 (2.8) 15 (7.5)
Total bilirubin 0 (0.0) 2 (1.0)
Elevated calciume 0 (0.0) 0 (0.0)
aNumber (%) of patients; bo (0.0) and 5 (2.5) cataracts respectively,
P= 0.026; cabnormality criteria: > 2.5 times the upper limit of reference
range; dp= 0.042; eabnormality criteria: > 1.25 times the upper limit of
reference range.
Table 7 Deaths during study
Treatment arm
Toremifene Tamoxifen
Cause of deatha (n = 214) (n = 201)
Disease progression 10 (4.7)b 9 (4.5)
Other malignancies 0 (0.0) 1 (0.5)
Respiratory system disorders 1 (0.5) 4 (2.0)
Vascular disorders 3 (1.4) 0 (0.0)
Gastrointestinal system disorders 0 (0.0) 1 (0.5)
Platelet, bleeding disorders 0 (0.0) 1 (0.5)
Other 0 (0.0) 4 (2.0)
Total 14 (6.5) 20 (10.0)
aBy WHO system organ class; bnumber (%) of patients.
The reasons for premature study drug discontinuations are
presented in Table 5. A total of 21 (9.8%) patients discontinued
TOR and 38 patients (18.9%) TAM, for various reasons (P =
0.011). Two of the TOR patients (0.9%) vs seven of the TAM
patients (3.5%) discontinued the treatment due either to toxicity or
to refusal.
Other treatment emergent adverse events are listed in Table 6.
Five patients developed cataracts while on TAM and none on TOR
(P = 0.026). Ofthe 13 other malignancies detected before the data
cut-off date, five were found among TOR patients and eight
among TAM patients. One endometrial carcinoma and two ovarian
cyst malignancies were observed among TAM patients, but no
gynaecological malignancies among TOR patients. Otherwise, the
distribution ofother malignancies was very similar. Elevated liver
enzyme, SGOT, was observed more frequently among TAM
patients than TOR patients (P = 0.042). The difference was still
of borderline significance (P = 0.082), when excluding the one
patient in TOR and three patients in the TAM group with liver
metastases.
There was no difference concerning fatal disorders (Table 7)
during or within 1 month after discontinuation of the treatment.
The majority of the deaths were due to metastatic breast cancer
and not related to treatment itself. There were no deaths directly
associated with the study drugs.
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The performance status and body weights of the patients were
similar in the treatment groups throughout the study.
DISCUSSION
This multicentre phase III study with two parallel groups
compared the efficacy and safety profile of TOR (60 mg daily)
with TAM (40 mg daily) as first-line treatment of inoperable
primary or metastatic ER-positive or undetermined breast cancer
in post-menopausal women. This is the only large-scale double-
blind trial comparing these two drugs (Pyrhonen, 1990). The
primary study variables were response rate, TTP, overall survival
and safety. In addition, variables such as TTF, time to onset of
response and response duration were followed. The response rate
was slightly higher forpatients on TAM, butthe difference was not
statistically significant. The strict criteria for efficacy assessment
and the great proportion of patients (43%) with tumours of
unknown ER status may explain the relatively low proportion of
objective responses in both treatment groups compared with those
encountered in the earlier phase II studies with TOR (Valavaara et
al, 1988; Hietanen et al, 1990; Tominaga et al, 1993).
At the time of closing the database for analysis, 19 patients
continued the treatment with TOR and 20 with TAM. The TTP
plot was in favour of TAM, but suggests a transient, rather than a
persistent difference between the treatment groups. Subgroup
analysis shows that the difference was essentially generated in the
patient group with tumours of unknown ER status. There was no
difference between the treatment groups if the patient population
with ER-positive tumours (n = 238) is considered separately.
There was, evidently, some major imbalance in receptor levels or
some other prognostic factors among the patients with unknown
ER status when compared with ER-positive tumour patients,
because the TTP was longer in the ER unknown group of TAM
patients (median 11.4 vs 10.1 months). As expected, the TTP was
shorter in TOR-treated patients with ER-unknown than ER-
positive tumours (median 6.3 vs 9.1 months). In previous studies,
positive correlation between ER concentration and TTP as well as
response duration has been reported for various hormonal treat-
ments ofbreast cancer (Bonomi et al, 1988; Valavaara et al, 1990).
In addition, the ER concentrations were higher in the TAM
patients with known ER status in the present study. Considering
that more patients on TAM than on TOR discontinued the study
prematurely, the TTF did not differ between the treatment groups.
At the time of closing the database, 18 patients with objective
response continued the study on TOR and 16 on TAM. There were
no significant differences between the treatment groups as regards
response duration or survival.
The present study indicates that in the treatment of metastatic
breast cancer TAM and TOR are equally safe and effective,
confirming the results of another large randomized trial (Hayes et
al, 1995). The toxicity was mostly mild or moderate and usually
attributable to the antioestrogenic/oestrogenic properties of the
study drugs. Significantly more patients experienced treatment-
emerged dizziness and cataract in the TAM group than the TOR
group. As no regularly performed eye examinations were orga-
nized in the study, the difference in the frequency ofcataracts must
be taken into account with great reservation. Considering previ-
ously reported oculartoxicity oftamoxifen (Gemer, 1989; Pavlidis
et al, 1992; Heier et al, 1994), this should be further explored
prospectively in other trials. The higher incidence of treatment
discontinuations due to toxicity or patient refusal in the TAM
group, may also reflect the somewhat higher toxicity of TAM in
the dose used in this study in comparison with TOR. Overall,
however, both treatments were well tolerated.
Preclinical toxicity data show that TOR is not carcinogenic,
whereas TAM has strong hepatocarcinogenicity in rats, which
suggests, potentially, an important safety advantage for TOR. In a
2-year mouse carcinogenicity study, TOR induced tumours in the
ovaries, bone and testes (to be published elsewhere). The corre-
sponding 2-year study with TAM is not available. Because
oestrogens cause similar tumours in mice, and TOR is mainly
oestrogenic in this species, these tumours are considered to be
species specific and to be oflittle clinical relevance to humans.
The widespread use of TAM in adjuvant medical therapy and
even as a chemopreventive agent has raised the question of its
safety in view of its carcinogenicity in animals. In adjuvant trials,
TAM has been shown to increase the incidence of uterine cancers
(Fornander et al, 1993; Fisher et al, 1994; De Gregorio et al, 1995;
Rutqvist et al, 1995), although the median follow-up times have
been less than 10 years. The expected time from tumour initiation
to clinically detectable cancer has been considered to be between
10 and 15 years. The mechanism ofTAM-induced carcinogenicity
may be partly hormonal (Metzler and Degen, 1987; Williams et al,
1993), i.e. promotion of existing tumours, and partly non-
hormonal, i.e. initiation of tumours or mutagenesis ofp53 tumour
suppressor gene (Styles et al, 1994; Vancutsem et al, 1994). As
TAM induces DNA adducts and is carcinogenic in the rat liver
(Han and Liehr, 1992; Hard et al, 1993; Hirsimaki et al, 1993;
Montandon et al, 1994), non-hormonal mechanisms might be pref-
erentially related to the initiation of secondary malignancies. The
recent report that TAM-treated patients have an increased inci-
dence of gastrointestinal tumours is disconcerting (Rutqvist et al,
1995). Studies have now been initiated to compare the genotoxic
potential ofTOR with TAM in adjuvant therapy ofbreast cancer.
In conclusion, the results of this double blind trial suggest that
TOR (60 mg day-') and TAM (40 mg day-') are equally effective
in the treatment of advanced ER-positive or ER-unknown breast
cancer in post-menopausal patients. The safety profile of TOR
makes it an attractive alternative to TAM, especially in long-term
treatment of breast cancer. The on-going comparative trials on
these drugs as an adjuvant treatment will further elucidate the
feasibility ofTOR in lesser stages ofbreast cancer. Exploration on
chemoprevention with TOR should also be considered.
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APPENDIX
The complete list of investigators and participating institutions
(number ofpatients)
Finland: S Pyrhonen, University Central Hospital Helsinki (92);
R Valavaara, University Central Hospital Turku (52); G Blanco,
S Virtanen, M Heikkinen, University Hospital Oulu (14); T
Hietanen, University Hospital Tampere (12); R Johansson,
University Hospital Kuopio (7); Sweden: H Modig, L Hardell,
Regional Hospital Ume'a (23); G Westman, J Ahlgren, Regional
Hospital Orebro (18); I Nilsson, Central Hospital Malmo (13); H
Sellstrom, Saffle Hospital (5); U Ljungqvist, Regional Hospital
Falun (4); U Glas, E Lidbrink, Sodersjukhuset of Stockholm (4);
J Jarhult, Regional Hospital Eksjo (3); P-E Josson, Regional
Hospital Helsingborg (1); Norway: S Gundersen, L Ottestad,
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Norwegian Radiumhospital Oslo (29); S Lundgren, S Kvinnsland,
Central Hospital Trondheim (15); 0 Mella, Haukeland Hospital
Bergen (13); Poland: M Pawlicki, J Rolski, Marie Sklodowska-
Curie Memorial Institute Cracow (35); J Zborzil, T Pienkowski,
Oncological Institute Warsaw (22); Czech Republic: J Bauer, I
Krajsova, 0 Pribylova, Charles University Hospital Prague (20);
I Bustova, Cesk6 Budejovice Hospital (9); M Svehelka,
Therapeutical Institute, Ples Hospital (4); Hungary: I Hindy,
National Institute of Oncology Budapest (8); G Laszl6, Veszprem
County Hospital (8); K Moskovits, Tetenyi Hospital Budapest (6);
M Osvath, Komarom County Hospital Tatabanya (6); L Perenyi,
Szeged University Hospital (1).
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